Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Hangzhou Tigermed Consulting Co's FCF Margin % or its related term are showing as below:
HKSE:03347'
s FCF Margin % Range Over the Past 10 Years
Min: 11.09 Med: 14.19 Max: 26.38
Current: 12.45
During the past 13 years, the highest FCF Margin % of Hangzhou Tigermed Consulting Co was 26.38%. The lowest was 11.09%. And the median was 14.19%.
HKSE:03347's FCF Margin % is ranked better than 76.85% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.39
vs HKSE:03347: 12.45
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou Tigermed Consulting Co FCF Margin % Chart
HKSE:03347 vs TMO, DHR, NTRA: FCF Margin % Comparison
For the Diagnostics & Research subindustry, Hangzhou Tigermed Consulting Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hangzhou Tigermed Consulting Co FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Hangzhou Tigermed Consulting Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Hangzhou Tigermed Consulting Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou Tigermed Consulting Co (HKSE:03347) has a FCF Margin % of 2.75% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Hangzhou Tigermed Consulting Co and its competitors. This is 81% below median its historical median of 14.19. Over the past decade, Hangzhou Tigermed Consulting Co's FCF Margin % has ranged from 11.09 to 26.38. According to the industry distribution chart, Hangzhou Tigermed Consulting Co ranks #47 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 23.2%.
Is Hangzhou Tigermed Consulting Co's FCF Margin % too high?
Hangzhou Tigermed Consulting Co's current FCF Margin % of 2.75% is 81% below median its 10-year median of 14.19. Over the past 10 years, this metric has ranged from a low of 11.09 to a high of 26.38. The Medical Diagnostics & Research industry median FCF Margin % is 0.39. Hangzhou Tigermed Consulting Co's value of 2.75% is 605.1% above this industry median. Based on the distribution chart, Hangzhou Tigermed Consulting Co ranks #47 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Hangzhou Tigermed Consulting Co has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Tigermed Consulting Co's FCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Hangzhou Tigermed Consulting Co ranks #47 out of 203 companies for FCF Margin %. This places Hangzhou Tigermed Consulting Co in the top 23% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 0.39. Hangzhou Tigermed Consulting Co's value of 2.75% is 605.1% above this benchmark. Historically, Hangzhou Tigermed Consulting Co's own FCF Margin % has ranged from 11.09 to 26.38 over the past decade. While the company's 10-year median is 14.19 vs. the industry median of 0.39, Hangzhou Tigermed Consulting Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
The median FCF Margin % among Medical Diagnostics & Research companies is 0.39, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hangzhou Tigermed Consulting Co's current FCF Margin % of 2.75% is 605.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Hangzhou Tigermed Consulting Co and its competitors. For the Medical Diagnostics & Research industry, the median FCF Margin % is 0.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hangzhou Tigermed Consulting Co's current FCF Margin % is 2.75%, which is 81% below median its own 10-year median of 14.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Tigermed Consulting Co stock overvalued right now?
Based on GuruFocus' analysis, Hangzhou Tigermed Consulting Co (HKSE:03347) is currently considered Fairly Valued. The stock's GF Value™ is HK$45.33, compared to a current price of HK$41.40 — trading 8.7% below its estimated fair value. The current FCF Margin % is 2.75%, which is 81% below median its 10-year median of 14.19 and 605.1% above the Medical Diagnostics & Research industry median of 0.39. Hangzhou Tigermed Consulting Co's overall GF Score™ is 92/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Hangzhou Tigermed Consulting Co (HKSE:03347), the current FCF Margin % is 2.75% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hangzhou Tigermed Consulting Co (HKSE:03347) Overvalued in 2026?
Based on GuruFocus' analysis, Hangzhou Tigermed Consulting Co stock appears to be undervalued.
The current stock price of HK$41.40 is trading 8.7% below its estimated GF Value™ of HK$45.33.
GuruFocus considers Hangzhou Tigermed Consulting Co to be Fairly Valued.
Key valuation signals for HKSE:03347:
FCF Margin %: 2.75% (81% below median its 10-year median of 14.19)
GF Value™: HK$45.33 vs. price of HK$41.40 (8.7% below fair value)
Industry Position: 605.1% above the Medical Diagnostics & Research median (#47 of 203)
No single metric tells the full story. See the HKSE:03347 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hangzhou Tigermed Consulting Co Ltd is a China-based provider of comprehensive biopharmaceutical R&D services, with an expanding world-wide presence. The Group is principally engaged in CRO services.
92GF Score
Get the complete analysis for HKSE:03347
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:03347 has been successfully added to your 
